Alkermes (ALKS) vs Amneal Pharmaceuticals (AMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Alkermes (ALKS) over the past year, gaining 89.7% versus a gain of 33.9%. Over five years, AMRX leads with a +248.4% price change compared with +30.9% for ALKS. Alkermes is the larger company by market cap ($6.95 billion vs $6.84 billion), about 1.0 times the size, while Amneal Pharmaceuticals is growing revenue faster (+8.0% vs -5.2%).
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (16.5x vs 22.9x for Alkermes). Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | AMRX |
|---|---|---|
| Share price | $41.45 | $19.65 |
| Market cap | $6.95B | $6.84B |
| 1-day change | -0.49% | -3.18% |
| YTD return | +48.12% | +55.95% |
| 1-year return | +33.91% | +89.67% |
| 5-year return | +30.87% | +248.40% |
| P/E ratio (TTM) | 109.07 | 40.10 |
| Forward P/E | 22.92 | 16.48 |
| EPS (TTM) | $0.38 | $0.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $3.02B |
| Revenue growth (YoY) | -5.25% | +8.05% |
| Net income (latest FY) | $241.66M | $72.06M |
| Gross margin | 86.69% | 36.88% |
| Operating margin | 17.21% | 13.05% |
| Net margin | 16.37% | 2.39% |
| 52-week high | $55.67 | $21.18 |
| 52-week low | $27.00 | $9.56 |
| Distance from 52-week high | -25.55% | -7.20% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.47% | +15.57% |
| Average volume | 1.83M | 2.22M |
| Shares outstanding | 167.76M | 348.30M |
| Employees | 2,050 | 8,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed ALKS by 55.8 percentage points over the past year.
- Alkermes trades at a higher earnings multiple (109.1x vs 40.1x trailing P/E).
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
- Amneal Pharmaceuticals grew revenue faster in its latest fiscal year (+8.05% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
ALKS vs AMRX FAQ
Which is bigger, Alkermes or Amneal Pharmaceuticals?
Alkermes (ALKS) is larger, with a market capitalization of $6.95B compared with $6.84B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, ALKS or AMRX?
AMRX returned +89.67% over the past 12 months, compared with +33.91% for ALKS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALKS or AMRX?
AMRX has the lower trailing P/E at 40.1, versus 109.1 for ALKS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alkermes and Amneal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.